The MHRA updated its list of new manufacturing and wholesale dealer licences on 7 May 2026, adding the latest May 2026 file. The page explains that it lists sites granted manufacturer or wholesale dealer licences and is updated monthly.
For businesses looking at medicines wholesale, this is a useful reminder.
The market is active.
Businesses are still applying, entering and expanding.
But in medicines wholesale, market entry is not just about opportunity. It is about readiness.
What Happened and Why It Matters
The MHRA’s latest update shows that new authorisations continue to be recorded in the UK medicines manufacturing and wholesale space.
That matters because every new entrant or expanding operator needs to understand that this sector is regulated from the start.
Medicines are not ordinary goods.
A business cannot simply decide to buy, store and supply medicines without understanding the licensing position, GDP requirements, Responsible Person arrangements and operational controls needed.
The first question should not be:
- Can we enter this market?
- The better question is:
- Are we genuinely ready to enter this market properly?
What This Means for Businesses
MHRA guidance states that individuals or companies selling or supplying human medicines to anyone other than the patient must have a wholesale distribution licence. It also explains that a wholesale distribution licence allows wholesale sale or supply of pharmacy, prescription-only, traditional herbal and general sales list medicines.
The guidance also says applications are assessed by the MHRA and should take 90 working days to process. It explains that, after inspection, wholesale distributors receive a certificate of Good Distribution Practice for each inspected site when the inspector is satisfied that issues have been addressed.
For a business, this means the application is not just paperwork.
It is a test of whether the operating model behind the application is credible.
Before applying, a business should understand:
- What activity it wants to carry out
- Whether the activity requires a WDA(H)
- Whether premises, people and systems are suitable
- Whether a Responsible Person structure is realistic
- Whether GDP procedures are written and workable
- Whether suppliers and customers can be checked properly
- Whether storage, records, transport and recall processes are controlled
- Whether the business can explain and evidence its model
- Why WDA(H) Readiness Is More Than a Form
A WDA(H) application should never be treated as a form-filling task.
The form is only one part of the process.
Behind it, the business needs a real operating structure.
That means having clear answers to practical questions such as:
- Who is responsible for GDP oversight?
- How will suppliers be approved?
- How will customers be qualified?
- How will medicines be stored?
- How will records be maintained?
- How will complaints, deviations and recalls be handled?
- How will staff be trained?
- How will the Responsible Person maintain visibility?
- How will the business keep systems updated after approval?
If these answers are unclear, the business may not be ready.
What Businesses Should Check Now
If your business is considering WDA(H) application, medicines wholesale market entry or specialist distribution planning, now is the time to check the foundations.
Start with these questions:
- Is the proposed activity clearly defined?
- Is the correct authorisation route understood?
- Is the Responsible Person role planned properly?
- Are GDP procedures drafted and practical?
- Are premises, storage and transport arrangements suitable?
- Are supplier and customer checks designed?
- Are records and traceability processes clear?
- Is there a recall and returns process?
- Is there a deviation and CAPA process?
- Has the business reviewed gaps before applying?
These questions help avoid wasted time, avoidable cost and preventable risk.
How Stag Global Helps
Stag Global does not supply medicines or products.
We help businesses understand whether they are ready before they move forward.
This may include:
- WDA(H) application readiness support
- GDP audit and readiness review
- Responsible Person / GDP quality support
- Compliance route reviews
- Supplier and customer qualification review
- Inspection readiness support
- Ongoing compliance support
- Specialist medicines wholesale and distribution planning
Our role is to help businesses see the route clearly, identify gaps early and move forward with stronger control.
We do not encourage shortcuts.
We help clients build the right foundations first.
Final Thought
The MHRA’s monthly licence updates show that new activity continues in this regulated market.
That is positive for serious businesses.
But regulated opportunity needs regulated readiness.
Before applying, entering or expanding, businesses should ask one simple question:
Can we evidence, control and defend the route we are building?
Book a confidential consultation with Stag Global to review your readiness, route and compliance position before moving forward.
